Mood stabilizers are a class of psychotropic medications primarily used to treat bipolar affective disorder (BAD) and other conditions involving severe mood swings or instability. They help control the frequent fluctuation of mood at short intervals and are utilized as maintenance drugs to prevent relapses.

Mood stabilizers are psychotropic drugs which are used in controlling mood disorders. They are essential for managing the extreme highs and lows associated with bipolar disorders and related psychiatric conditions.

• No consensus definition: Officially, the FDA states, "There is no such thing as a mood stabilizer."
• Clinical Definition (Sachs, 1996): Any medication that is able to decrease vulnerability to subsequent episodes of mania or depression; and does not exacerbate the current episode or maintenance phase of treatment.
• Important Rule: Patients with acute-phases of mania or depression should generally be treated first with anti-psychotics or anti-depressants respectively, alongside or before transitioning to maintenance mood stabilizers.

• 1817: Lithium was discovered as a chemical element.
• 1871: First recorded use as a treatment of mania.
• 1876: Li₂CO₃ used in the prevention of depression.
• Early 20th Century: Use of Lithium largely abandoned due to its severe toxicity.
• 1949: Use of Lithium for mania rediscovered by Australian psychiatrist John Cade.
• 1970: FDA approved the use of Lithium for mania.
• 1995: Sodium valproate approved for acute mania.

The exact mode of action of mood stabilizers is not fully understood, but three primary pharmacological theories explain their efficacy:

1. Neurotransmitter Regulation: Mood stabilizers regulate the levels of monoamine neurotransmitters (serotonin, dopamine, and norepinephrine). Imbalances lead to mood swings. Mood stabilizers normalize these imbalances, reducing bipolar symptoms.
2. Ion Channel Modulation (Voltage-Sensitive Channels): They modulate the activity of voltage-gated ion channels, particularly sodium (Na⁺) and calcium (Ca²⁺) channels. These channels regulate neuronal excitability. Abnormal activity leads to mania or depression; stabilization reduces this aberrant firing.
3. Structural and Signal Transduction Modulation: They affect the structure and function of brain regions regulating mood (prefrontal cortex, amygdala) by acting on downstream signal transduction cascades (e.g., G-proteins, second messengers like inositol monophosphate, and enzymes like GSK-3 and PKC), promoting neuroprotection and long-term neuroplasticity.

• Lithium: The gold standard element.
• Anticonvulsants: Carbamazepine, Sodium Valproate, Lamotrigine, Gabapentin, Pregabalin, Topiramate.
• Atypical Antipsychotics: Olanzapine, Quetiapine, Risperidone, Aripiprazole.

Lithium is a naturally occurring element. It is the classic mood stabilizer, possessing profound anti-manic and anti-suicidal properties.

Lithium carbonate is a medication that is commonly used as a mood stabilizer to treat bipolar disorder. It is a naturally occurring element that is found in small amounts in the body, and it works by affecting the levels of certain neurotransmitters in the brain, particularly serotonin and norepinephrine.

• Acute treatment of mania.
• Prophylaxis of bipolar affective disorder (More effective in preventing manic relapses than depressive relapses).
• Augmentation of antidepressants in treatment-resistant unipolar depression.
• Prevention of aggressive behavior in patients with learning difficulties or personality disorders.
• Schizoaffective disorder and Alcoholism.

Exact mechanism is uncertain, but it works by affecting signal transduction:

• Through the inhibition of 2nd messenger enzymes (e.g., inositol monophosphate).
• By modulation of G proteins.
• By interaction at various sites within downstream signal transduction cascades (e.g., inhibition of Glycogen Synthase Kinase-3 [GSK3] and Protein Kinase C [PKC]).
• Cerebral sodium concentration is reduced, which helps control mania and reduces excitements.

For adults:

• The typical starting dose of lithium carbonate for the treatment of bipolar disorder is 300-600 mg per day, divided into two or three doses.
• The dosage is then gradually increased, usually by 300-600 mg per week, until a therapeutic blood level is achieved.
• Maintenance doses of lithium carbonate can range from 600-2400 mg per day, depending on the individual’s needs and the therapeutic blood level.

For children:

• Lithium carbonate is not typically prescribed for children under the age of 12, as there is limited research on its safety and efficacy in this population.
• For adolescents aged 12-18, the starting dose of lithium carbonate is 300 mg per day, divided into two or three doses.
• The dosage is then gradually increased as needed, usually by 150-300 mg per week, until a therapeutic blood level is achieved.

Lithium has a very narrow therapeutic index. Monitoring is critical for patient survival.

Test / Parameter	Details & Frequency
Pre-Lithium Workup	Renal functions (BUN, Creatinine, GFR), Thyroid functions (TFTs), ECG (for cardiac risks), FBS, electrolytes, complete blood count (CBC), Urinalysis, Pregnancy test.
Plasma Level Monitoring	Check at 1st 4-7 days → 2 weekly until satisfactory → 6 weekly → 3 monthly when stable. Blood drawn 12-14 hours post-dose.
Therapeutic Plasma Levels	Prophylaxis: Minimum effective: 0.4 mmol/L. Optimal range: 0.6 - 0.75 mmol/L (up to 1.2 mEq/L). Acute Mania: 0.8 - 1.0 mmol/L (up to 1.2 mEq/L). Toxic Level: > 1.5 mmol/L (Early), > 2.0 mmol/L (Serious/Lethal).
Long-term Routine Tests	GFR and TFTs every 6 months.

Note: When one is on lithium carbonate, the following base line investigations should be done:

• Blood serum lithium level:
  • The normal range 0.6-1.2 mEq/l (for prevention of relapse in BAD).
  • Therapeutic levels 0.8-1.2mEq/l (for treatment of acute mania).
  • Toxic lithium levels greater than 2.0 mEq/l.
• Blood tests: A complete blood count (CBC) and blood chemistry panel should be done to assess the person’s overall health and to check for any underlying medical conditions that could affect their response to lithium. The blood chemistry panel should include tests for electrolyte levels (including sodium and potassium), kidney function, liver function, and thyroid function.
• Urinalysis: A urinalysis should be done to assess kidney function and to check for any signs of kidney damage.
• ECG: An electrocardiogram (ECG) should be done to assess the person’s heart function and to check for any underlying cardiac conditions that could affect their response to lithium.
• Pregnancy test: Women of childbearing age should have a pregnancy test before starting lithium, as this medication can be harmful to a developing fetus.
• Medical history: A thorough medical history should be taken to assess the person’s overall health, including any past or current medical conditions, medications, or allergies.
• Psychiatric evaluation: A comprehensive psychiatric evaluation should be done to assess the person’s symptoms and to establish a diagnosis of bipolar disorder.
• Baseline mood assessment: A baseline assessment of the person’s mood and behavior should be done to establish a baseline for monitoring the effects of the medication.

N.B: A patient on lithium carbonate should also be given a thyroxin tablet (also known as levothyroxine), a medication that is used to treat an underactive thyroid gland (hypothyroidism). This is because lithium can affect the functioning of the thyroid gland.

Lithium carbonate is generally well-tolerated when used as a mood stabilizer for the treatment of bipolar disorder. However, like any medication, it can cause side effects, both in the short term and the long term.

• Nausea, vomiting, and diarrhea
• Dry mouth and thirst
• Increased urination
• Muscle weakness and tremors
• Fatigue and drowsiness
• Headaches
• Increased appetite and weight gain
• Mild cognitive impairment (difficulty with attention, memory, or problem-solving)
• Skin rash or acne
• Vertigo
• Dysarthria (impaired articulation of speech)
• Cardiac arrhythmias
• In some patients they may have oedema
• Nystagmus

Many of these side effects are usually mild and may resolve on their own as the body adjusts to the medication. Some people may be able to manage these side effects by adjusting the dosage or timing of their medication, or by taking it with food or milk.

• Kidney damage or kidney failure
• Hypothyroidism (underactive thyroid gland) i.e. reduced thyroxin in the body as lithium carbonate interferes with metabolism
• Increased risk of diabetes mellitus
• Cardiovascular disease (heart disease)
• Neurological effects (such as hand tremors, slurred speech, and impaired coordination)
• Teratogenicity (birth defects in fetuses exposed to lithium during pregnancy)
• Nephrogenic diabetes insipidus
• Depletion of calcium in bones
• Memory impairment affects memory centers of the brain.

NB: Big doses of neuroleptics e.g. haloperidol when used together with lithium for a long time may cause irreversible toxic encephalopathy.

• Allergies: People who are allergic to lithium carbonate or any of its ingredients should not take this medication.
• Kidney disease: Lithium is primarily excreted by the kidneys, and people with kidney disease may be at risk of toxicity if they take lithium. Lithium is contraindicated in people with severe kidney disease or end-stage renal disease.
• Dehydration: Lithium can affect the body’s electrolyte balance, particularly sodium, and dehydration can increase the risk of toxicity. People who are dehydrated or at risk of dehydration should not take lithium.
• Cardiovascular disease: Lithium can affect the cardiovascular system, and people with a history of heart disease or other cardiovascular conditions may be at increased risk of complications if they take lithium.
• Pregnancy and breastfeeding: Lithium can cross the placenta and pass into breast milk, and it may be harmful to a developing fetus or nursing infant. Lithium is contraindicated during pregnancy and breastfeeding, unless the benefits outweigh the risks (Note: known to cause Ebstein's anomaly).
• Low sodium levels: Lithium can cause or worsen hyponatremia (low sodium levels in the blood), which can be life-threatening. Lithium is contraindicated in people with severe or uncontrolled hyponatremia.
• Seizures: Lithium can lower the seizure threshold, and it is contraindicated in people with a history of seizures or epilepsy.
• Thyroid disease: Lithium can affect thyroid function and may exacerbate hypothyroidism (an underactive thyroid). Lithium is contraindicated in people with severe hypothyroidism.

• > 1.5 mmol/L (Early toxic effects): GI effects (increasing anorexia, nausea, vomiting, diarrhea), CNS effects (muscle weakness, drowsiness, ataxia, coarse tremor, poor coordination, slurring of speech, confusion, muscle twitching).
• > 2.0 mmol/L (Serious toxic effects): Disorientation, seizures, coma, death. Irreversible toxic encephalopathy can occur, especially if combined with high-dose neuroleptics (e.g., haloperidol).

Mostly involve reduced plasma Na (Sodium) levels. The kidney cannot easily differentiate Lithium from Sodium. If Sodium drops, the kidney reabsorbs Lithium, causing fatal toxicity.

• Low salt diet or Dehydration (heavy sweating, outdoor labor).
• Drug interactions: Diuretics (esp. Thiazides), NSAIDs, ACE inhibitors, Angiotensin II receptor blockers (ARBs), and some antibiotics like metronidazole.

1. Stop taking lithium: The person should stop taking lithium immediately to prevent further toxicity.
2. Assess serum lithium levels, electrolytes, renal functions, ECG.
3. Fluid and electrolyte replacement: Intravenous fluids may be given to help flush out the excess lithium from the body and to restore electrolyte balance.
4. Supportive care: The person may need to be hospitalized for close monitoring of their vital signs and mental status. In severe cases, mechanical ventilation and dialysis may be necessary.
5. Extra NaCl to stimulate osmotic diuresis and compete with lithium reabsorption.
6. Pharmacological treatment: Depending on the severity of the symptoms, the person may be given medications to help control nausea, vomiting, seizures, or other symptoms.
7. Gastric lavage, emesis, or activated charcoal for acute short-time ingestion.
8. If level > 3.0 mmol/L (or severe symptoms): Peritoneal dialysis or Haemodialysis is indicated to wash the lithium out of the blood.

There is a high risk of manic relapse (even in patients symptomless for 5 years). It is recommended not to start Lithium without an intention to continue for at least 3 years. Discontinuation should be done slowly over at least 1 month.

• Assessment: Nurses should perform a thorough assessment of the patient before starting lithium treatment, including a physical examination, medical history, and laboratory tests to establish baseline values. Nurses should also monitor the patient regularly for potential side effects or adverse reactions.
• Education: Nurses should educate the patient and their family members about the proper use of lithium, including the dosage, timing, and potential side effects. They should also instruct the patient to avoid dehydration and to maintain a consistent level of sodium intake.
• Medication administration: Nurses should administer lithium carbonate according to the prescribed dosage and timing. They should also monitor the patient’s compliance with the medication regimen and report any missed doses or concerns to the healthcare provider.
• Monitoring: Nurses should monitor the patient regularly for potential side effects or adverse reactions, such as tremors, confusion, or kidney dysfunction. They should also monitor the patient’s blood levels of lithium, electrolytes, and kidney function regularly and report any abnormalities to the healthcare provider.
• Collaboration: Nurses should collaborate with the healthcare provider and other members of the healthcare team to ensure the safe and effective use of lithium carbonate. They should also communicate any concerns or changes in the patient’s condition to the healthcare provider in a timely manner.

1. Lithium must be taken on regular basis, preferably at the same time daily. For example, a client taking lithium on TID schedule, who forgets a dose, should wait until the next scheduled time to take lithium and not take twice the amount at one time, because lithium toxicity can occur.
2. When lithium therapy is initiated, mild side effects such as fine tremors, increased thirst and urination, nausea, anorexia etc may develop.
3. Serious side effects of lithium that necessitate its discontinuance include vomiting, extreme hand tremors, sedation, muscle weakness and vertigo. The psychiatrist should be notified immediately if any of these effects occur.
4. Since polyurea can lead to dehydration with risk of lithium intoxication, patients should be advised to drink water to compensate for the fluid loss.
5. Various situations can require an adjustment in the amount of lithium administered to a client, such as the addition of a new medicine to the client’s drug regimen, a new diet or an illness with fever or excessive sweating. People involved in heavy outdoor labor are prone to excessive sweating and sodium loss through sweating. Must be advised to consume large quantities of water with salt, to prevent lithium toxicity due to decreased sodium levels.
6. Frequent serum lithium level evaluation is important. Blood for determination of lithium levels should be drawn in the morning approximately 12-14 hours after the last dose was taken.
7. The patient should be told about the importance of regular follow up. In every six months, a blood sample should be taken for estimation of electrolytes, urea, creatinine, a full blood count, and thyroid function test.

An anticonvulsant that acts as a highly effective mood stabilizer. Believed to be more effective than Lithium in treating rapid cycling and mixed episodes of mania.

Sodium valproate is a medication used to treat a variety of neurological and psychiatric conditions. It belongs to a class of drugs called anticonvulsants, which are typically used to treat epilepsy, but sodium valproate has also been found to be effective in treating bipolar disorder, migraine headaches, and certain types of seizures.

• Epilepsy: Used to prevent and control seizures in patients with epilepsy, including generalized and partial seizures, absence seizures, and myoclonic seizures.
• Bipolar disorder: Used as a mood stabilizer in the treatment of bipolar disorder, which is characterized by episodes of mania and depression.
• Migraine prophylaxis: Sometimes used to prevent migraines, particularly in patients who do not respond to other treatments.
• Neuropathic pain: May be used to treat certain types of neuropathic pain, such as trigeminal neuralgia and diabetic neuropathy.
• Agitation and aggression: May be used to treat agitation and aggression in patients with dementia, autism, or other psychiatric conditions.
• Alcohol withdrawal: May be used to treat alcohol withdrawal symptoms, such as seizures and delirium tremens.
• Treatment of acute mania, prophylaxis of bipolar disorder, Epilepsy (all forms, drug of choice in myoclonic seizures), migraine prophylaxis, neuropathic pain, agitation in dementia, alcohol withdrawal. Shown to be useful for patients unresponsive to Lithium and Carbamazepine.

Sodium valproate works by increasing the levels of a neurotransmitter called gamma-aminobutyric acid (GABA) in the brain (by inhibiting GABA transaminase), which helps to calm overactive neurons and prevent seizures. It also blocks voltage-gated sodium channels. It has mood-stabilizing properties that make it effective in treating bipolar disorder.

90% bound to plasma albumin. Three possibilities:

1. Inhibition of voltage-sensitive Na+ channels (VSSC) – Diminishes excitatory glutamate neurotransmission.
2. Enhancing actions of GABA – Promotes inhibitory neurotransmission by inhibiting GABA transaminase (the enzyme that breaks down GABA).
3. Regulating downstream signal transduction cascades – Promotes neuroprotection and long-term plasticity.

• For Epilepsy:
  • Adults: Usual starting dose is 600-1000 mg per day, divided. Maintenance up to 2500-3000 mg per day.
  • Children: Starting dose is usually 10-15 mg/kg/day. Maintenance up to 30-60 mg/kg/day.
  • Elderly: Starting dose may be lower, around 250-500 mg per day. Maintenance up to 2000 mg per day.
• For Bipolar Disorder:
  • Adults: Starting dose is usually 500-750 mg per day, divided. Maintenance up to 2000-2500 mg per day.
  • Children: Starting dose is usually 10-15 mg/kg/day. Maintenance up to 60 mg/kg/day.
  • Elderly: Starting around 250-500 mg per day. Maintenance up to 2000 mg per day.

• Gastrointestinal effects: Nausea, vomiting, diarrhea, and abdominal pain are common.
• Weight gain: Can cause weight gain and changes in appetite.
• Sedation and drowsiness: Can affect the ability to operate machinery or drive.
• Tremor: Involuntary movements of the hands, arms, or other body parts.
• Hair loss (Alopecia): Can cause hair loss, although this side effect is usually reversible.
• Liver toxicity (Hepatotoxicity): Can cause severe liver toxicity, especially those taking other medications affecting the liver. Requires LFT monitoring.
• Blood disorders: Can affect blood cells, leading to anemia, low platelet counts (thrombocytopenia), and increased risk of bleeding.
• Pancreatitis: In rare cases, can cause severe inflammation of the pancreas, a potentially life-threatening condition.

• Hypersensitivity: Should not be used in patients who have had an allergic reaction.
• Liver disease: Can cause liver toxicity, so it should be avoided in patients with pre-existing liver disease or abnormal LFTs.
• Pancreatitis: Should not be used in patients with a history of pancreatitis.
• Pregnancy: Can cause severe birth defects (e.g., neural tube defects like spina bifida) and developmental problems. Avoided in pregnant women.
• Breastfeeding: Passes into breast milk and can harm a nursing baby.
• Urea cycle disorders: Can cause fatal hyperammonemia in patients with urea cycle disorders.

• GI disturbances, tremor, sedation, tiredness (common).
• Weight gain & Transient hair loss (alopecia).
• Hepatotoxicity: Elevation of liver enzymes.
• Hematologic: Thrombocytopenia, inhibition of platelet aggregation, anemia.
• Pancreatitis: Acute, potentially life-threatening.
• Polycystic ovarian disease (PCOS) & Rashes.
• Teratogenicity: Spina bifida, ASD, cleft palate, hypospadias, polydactyly, craniosynostosis.

Carbamazepine is a medication used primarily to treat seizures and nerve pain, such as trigeminal neuralgia. It works by reducing the excessive electrical activity in the brain that can cause seizures and by reducing the sensitivity of nerve fibers, which can help to relieve pain. Carbamazepine belongs to a class of medications called anticonvulsants, which are also used to treat bipolar disorder and mood disorders.

Mechanism of Action:

• Blocks voltage-sensitive Na+ channels (VSSC) at a site within the channel on the alpha subunit.
• Reduces glutamate release.
• Decreases turnover of norepinephrine and dopamine.
• Facilitates 5HT (serotonin) neurotransmission.

Pharmacological Note: It acts by prolonging the inactivated state of voltage-gated sodium channels. It also exhibits auto-induction of hepatic CYP450 enzymes.

• In epilepsy especially in complex partial seizure (drug of choice).
• Rapid cycling bipolar disorder.
• Acute mania.
• Trigeminal neuralgia i.e. inflammation of the trigeminal nerve (absolute drug of choice).
• Herpes zoster (post-herpetic neuralgia).
• Schizoid affective disorder.

• Children: Starting dose for epilepsy is usually 10-20 mg/kg/day, divided. Max 1000 mg/day. For trigeminal neuralgia, 100 mg/day divided.
• Adults: Starting dose for epilepsy is usually 200-400 mg/day, divided into two or three doses. Max 1200 mg/day. For trigeminal neuralgia, 100-200 mg/day.
• Elderly: Starting dose may be lower due to age-related changes in metabolism and potential for side effects. Carefully monitor and adjust.

• Dizziness or drowsiness.
• Nausea or vomiting.
• Headache.
• Blurred vision or double vision (diplopia).
• Skin rash or itching.
• Dry mouth, constipation, or diarrhea.
• Swelling or fluid retention (edema).
• Unsteadiness (ataxia) or loss of coordination, fatigue, weakness.

More serious adverse effects may occur with carbamazepine, and require immediate medical attention. These can include:

• Severe skin reactions: such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). (HLA-B*1502 genetic testing is recommended for at-risk Asian populations).
• Blood disorders: such as agranulocytosis or aplastic anemia.
• Liver damage or hepatitis.
• Allergic reactions, including anaphylaxis.
• Increased risk of suicidal thoughts or behaviors.
• Drug Interactions: It induces liver enzymes, causing birth control pills (oral contraceptives) to be less effective, leading to unintended pregnancies.
• Drowsiness, dizziness, ataxia, diplopia (double vision), nausea – common at beginning.
• Hematologic: Agranulocytosis (Rare 1:10000 to 1:25000), Relative leucopenia (common), aplastic anemia.
• Dermatologic: Rashes (5%), Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis).
• Hepatic & Endocrine: Elevation of LFTs (Hepatitis - rare), reduces plasma thyroxin level (clinical hypothyroidism is rare).
• Disturbance of cardiac conduction.
• Teratogenicity: Neural tube defects. Causes birth control pills to be less effective (CYP450 inducer).

• Hypersensitivity or allergy: to carbamazepine or tricyclic antidepressants.
• Bone marrow suppression: Can cause a decrease in blood cell production. Do not use in individuals with blood disorders.
• History of agranulocytosis: A severe decrease in white blood cells.
• Use of MAO inhibitors: Should not be used in combination with monoamine oxidase (MAO) inhibitors (can cause a life-threatening crisis).
• Pregnancy: Can cause harm to a developing fetus (neural tube defects).
• Breastfeeding: Present in breast milk and may cause harm to a nursing infant.

Monitoring: Baseline FBC, BU, SE, LFT, Weight. Repeat in 6 months. Use adequate contraception in women of childbearing age + Folic acid 5mg/daily. Avoid MAOIs.

• Structurally related to carbamazepine (it is a prodrug).
• Active form: eslicarbazepine.
• Mechanism of action is similar to carbamazepine.
• Less sedating, less bone marrow toxicity, and less hepatic enzyme inducing than carbamazepine.
• Mood stabilizer effects are not definitively proven, but it is used off-label due to better tolerability than carbamazepine (especially for mania).

• Indications: Acute treatment of bipolar depression and prophylaxis for bipolar depression. Used alone, it does not have significant acute or prophylactic anti-manic actions.
• Mechanism of Action: Similar to carbamazepine. Blocks VSSC (alpha subunit) and reduces excitatory glutamate neurotransmission.
• Adverse Effects: Nausea, headache, diplopia, blurred vision, dizziness, ataxia, tremor.
  • Skin Rashes (3%): Usually maculopapular. However, it carries a severe Black Box Warning for life-threatening rashes: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Requires very slow dose titration.
  • Angioedema.
  • Risk of cleft palate in women of childbearing age (low risk).

• Structural analogues of GABA.
• Mechanism of action: Inhibition of the alpha-2 delta subunit of voltage-gated Ca++ channels.
• Not considered to be effective primary mood stabilizers.
• They possess anxiolytic, sedative, and analgesic properties, making them useful as adjunctive treatments to other mood stabilizers to control anxiety or sleep disturbances.

• Anticonvulsant and antimigraine drug. Not clearly effective as a standalone mood stabilizer.
• Mechanism of action: Enhance GABA function and reduce glutamate function by interfering with Na+ and Ca++ channels.
• Useful as an adjunctive treatment in bipolar disorder primarily by reducing weight gain, insomnia, and anxiety (often counteracting the weight gain caused by Lithium or Valproate). Cognitive dulling is a common side effect.

Agents such as Olanzapine, Quetiapine, Risperidone, and Aripiprazole.

• Atypical antipsychotics are proven to be highly effective in treating acute mania and preventing the recurrence of mania.
• Newer data suggests certain atypicals (e.g., Quetiapine, Lurasidone) are effective in treating bipolar depression and preventing the recurrence of depression.
• Proposed Mechanisms:
  • 5HT2A antagonism: Reduces glutamate hyperactivity (an action shared by several anticonvulsant mood stabilizers).
  • Increasing monoamine neurotransmitters (5HT, NA, DA): Important in improving mood in the depressive phases.

The majority of bipolar patients need treatment with several medications. Combining agents allows doses of each agent to be lowered to tolerable levels, and synergy provides greater efficacy than a single agent in high doses.

• Atypical Antipsychotic + Lithium
• Atypical Antipsychotic + Valproate
• Lithium + Valproate
• Lamotrigine + Valproate (Note: Valproate inhibits the metabolism of Lamotrigine, doubling its levels. Lamotrigine dose must be drastically reduced to avoid SJS).
• Lamotrigine + Lithium
• Lamotrigine + Lithium + Valproate

• Lithium + Carbamazepine: High risk of severe Neurotoxicity.
• Lamotrigine + Carbamazepine: Increased neurotoxicity and unpredictable pharmacokinetic interactions (CBZ induces Lamotrigine metabolism).

No.	Nursing Responsibility / Diagnosis	Interventions & Rationale
1	Pre-Treatment Workup & Assessment	Perform a thorough assessment before starting treatment (Physical exam, history). Ensure baseline labs are drawn: ECG, FBS, Creatinine, Electrolytes, Urinalysis, and TFTs. Rationale: Renal side effects are common; drug is dangerous in compromised kidneys. It also depresses the thyroid gland.
2	Medication Administration & Dosing Adherence	Administer on a regular basis, preferably at the same time daily. Missed Dose Protocol: If a client on a TID schedule forgets a dose, they should wait until the next scheduled time. Never double the dose. Rationale: Doubling the dose easily triggers acute Lithium toxicity due to the narrow therapeutic index.
3	Risk for Imbalanced Fluid Volume (The Sodium Connection)	Massive Clinical Point: Maintain a consistent, adequate sodium and fluid intake (2-3 liters/day). Rationale: If the patient sweats heavily (losing sodium), the kidney reabsorbs Lithium instead of Sodium, leading to rapid, fatal toxicity. Never put a Lithium patient on a low-sodium diet or administer loop/thiazide diuretics without extreme caution.
4	Monitoring for Toxicity & Adverse Effects	Monitor for mild expected side effects (fine tremors, polyuria, thirst, nausea) vs. severe toxic effects (vomiting, extreme hand tremors, sedation, muscle weakness, vertigo, ataxia). If toxic signs appear, hold the medication and notify the psychiatrist immediately. Monitor Lithium blood levels: Draw blood in the morning, approximately 12-14 hours after the last dose.
5	Patient Education & Collaboration	Educate the patient/family on proper dosage, recognizing toxicity signs, and avoiding dehydration. Warn against taking OTC NSAIDs (like Ibuprofen) which can increase Lithium levels. Ensure regular follow-up every 6 months for electrolytes, urea, creatinine, CBC, and TFTs.

• American Psychiatric Association. (2020). Practice Guideline for the Treatment of Patients With Bipolar Disorder.
• Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2017). Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.
• Katzung, B. G. (2017). Basic & Clinical Pharmacology (14th ed.). McGraw-Hill Education.
• Sachs, G. S. (1996). Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. Journal of Clinical Psychopharmacology.
• Provided Presentation Slides and Lecture Notes on Mood Stabilizers (Source Material).